Posted by Michael Wonder on 26 Jul 2026
Otsuka receives FDA approval for first in class Simtriyo (centanafadine) for the treatment of attention-deficit hyperactivity disorder in adults and paediatric patients aged 6 years and older
24 July 2026 - Simtriyo will be commercially available later this year following scheduling by the US Drug Enforcement Administration.
Otsuka today announced that the US FDA has granted approval of Simtriyo (centanafadine), a once daily extended release capsule for the treatment of attention deficit hyperactivity disorder in adults and pediatric patients aged 6 years and older weighing at least 20 kg.
